socalTECH

AUGUST 4, 2014

San Diego-based Otonomy , which is developing treatments for diseases of the inner and middle ear, set its estimated IPO pricing range Friday. The company is venture backed by Avalon Ventures, OrbiMed, Novo AS, TPG Biotech, Domain Associates, Rivervest Venture Partners, as well as others. and $16.00 READ MORE>>.

Pricing 147

Pricing Avalon San Diego Acquisition 147

socalTECH

JANUARY 17, 2017

San Diego-based AnaptysBio , which develops antibodies for treating inflammation, has set its estimated IPO pricing range, saying on Tuesday that it expects to price its IPO at between $14.00 and $16.00 The company is selling 4,000,000 shares of its common stock on the NASDAQ Global Select Market as ANAB.

Pricing 113

Pricing Avalon Southern California Venice 113

socalTECH

JUNE 11, 2021

La Jolla-based biopharmaceuticals startup Janux Therapeutics said early this morning that it has priced its IPO, offering up 11,400,000 shares of its common stock at $17.00 Janux Therapeutics is developing T cell engager immunotherapies. Janux Therapeutics is developing T cell engager immunotherapies.

Pricing 113

Pricing Avalon Capital Marketing 113

socalTECH

AUGUST 13, 2014

San Diego-based biopharmaceuticals firm Otonomy was up today in early trading, after pricing 6.25 The company priced at the high end of its initial estimated IPO range, which was $14.00 The company priced at the high end of its initial estimated IPO range, which was $14.00 million shares of its common stock at $16.00

Avalon 138

Avalon San Diego Pricing Acquisition 138

socalTECH

JANUARY 26, 2017

San Diego-based AnaptysBio , which develops antibodies for treating inflammation, has raised $75.0M Anaptys priced its IPO on Wednesday night at $15.00 AnaptysBio is backed by Frazier Healthcare, Novo A/S, Avalon Ventures, Alloy Ventures, Biotechnology Value Fund, HBM Healthcare Investments, and others. READ MORE>>.

Avalon 113

Avalon San Diego Pricing Invest 113

socalTECH

SEPTEMBER 19, 2008

in funding from Venrock, Avalon, and Masthead. Derrick Oien: We have a platform we develop, called ANTHEM. Historically, it was something that started to develop before our launch with operators back in 2005, and it now serves as a laboratory for development of our product. Intercasting is backed by $17.5M a month.

Social Network 113

Social Network Anthem Mobile Java 113